8-K filed Aug 6, 2026 at 08:03 ET
Aurinia Pharmaceuticals reported Q2 2026 revenue of $83.2M (+19% YoY) and diluted EPS of $0.28 (+75% YoY), both exceeding consensus estimates. The company reiterated its full-year 2026 guidance for total revenue of $315M-$325M and LUPKYNIS net product sales of $305M-$315M, while also providing an update on the initiation of the PRESERVE Phase 4 study and the expansion of its aritinercept pipeline into four indications. The beat on both top and bottom lines, combined with maintained guidance, supports a positive read-through for the stock.